论文部分内容阅读
目的观察放疗联合长春瑞滨(NVB)、顺铂(DDP)治疗局部晚期非小细胞肺癌(NSCLC)的近期疗效及耐受性。方法40例局部晚期NSCLC患者,实施常规放疗,计划照射剂量60~70Gy/6~7周,1次/d,5次/周。在放疗的同时每周接受顺铂(DDP)30mg/m2的化疗,共用6周,于第1,8d接受长春瑞滨(NVB)25mg/m2的化疗,每3周1次。结果40例全部完成治疗计划,肺原发灶CR为12.5%(5/40),PR为67.5%(27/40),有效率为80.0%(32/40),NC和PD分别为12.5%(5/40)和7.5%(3/40),放射性肺炎发生率为17.5%(7/40),放射性食管炎发生率为32.5%(13/40),白细胞减少发生率为80.0%(32/40)。中位随访期为18(5~27)个月。结论放疗联合长春瑞滨、顺铂同步治疗局部晚期非小细胞肺癌近期疗效较好,能明显提高患者的生活质量,毒副反应能为大多数患者耐受。
Objective To observe the short-term efficacy and tolerability of radiotherapy combined with vinblastine (NVB) and cisplatin (DDP) in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods Forty patients with locally advanced NSCLC underwent routine radiotherapy at a dose of 60-70 Gy / 6-7 weeks, once / d and 5 times / week. Chemotherapy with cisplatin (DDP) 30 mg / m 2 weekly was administered concurrently with radiotherapy for 6 weeks, with vinorelbine (NVB) 25 mg / m 2 on days 1 and 8 every 3 weeks. Results All the 40 patients completed the treatment plan. The primary lung cancer CR was 12.5% (5/40), the PR was 67.5% (27/40), the effective rate was 80.0% (32/40), the NC and PD were 12.5% (5/40) and 7.5% (3/40) respectively. The incidence of radiation pneumonitis was 17.5% (7/40), the incidence of radiation esophagitis was 32.5% (13/40) and the incidence of leukopenia was 80.0% (32 / 40). The median follow-up period was 18 (5-27) months. Conclusion Radiotherapy combined with vinorelbine and cisplatin in the treatment of locally advanced non-small cell lung cancer has better curative effect in recent years, and can significantly improve the quality of life of patients. Toxicity and side effects can be tolerated in most patients.